The gap between knowledge and practice in the treatment and prevention of cardiovascular disease

Preventive Cardiology

Volumn 3, Issue 4, 2000, Pages 167-171

  Siegel, D ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPOCHOLESTEROLEMIC AGENT; WARFARIN;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MEDICAL EDUCATION; REVIEW;

EID: 0033769272     PISSN: 1520037X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2000.80381.x     Document Type: Review

References (60)

1. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management
2. Effects of enalapril on mortality in severe congestive heart failure
3. Underutilization of evidence-based therapy in heart failure
4. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure
5. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995
6. Prognosis of men after myocardial infarction: Mortality and first recurrence in relation to selected parameters
7. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
8. The beta-blocker heart attack trial (BHAT)
9. The Goteborg Metoprolol Trial in Acute Myocardial Infarction
10. Beta blockade during and after myocardial infarction: An overview of the randomized trials
11. Impact of clinical trials on the use of beta blockers after acute myocardial infarction and its relation to other risk indicators for death and 1-year mortality rate
12. Cardiologists' practices compared with practice guidelines: Use of beta-blockade after acute myocardial infarction
13. National use and effectiveness of beta-blockers for the treatment of elderly patients after myocardial infarction
14. Use of aspirin, β-blockers, and lipid-lowering medications before recurrent acute myocardial infarction
15. Atrial fibrillation: A major contributor to stroke in the elderly
16. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke
17. Atrial fibrillation: Risk factors for embolization and efficacy of antithrombotic therapy
18. National patterns of warfarin use in atrial fibrillation
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
20. Reduction in cardiovascular events during pravastatin therapy
21. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
22. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
23. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
24. Populations awareness and control of hypertension and hypercholesterolemia
25. Trends in cholesterol knowledge and screening and hypercholesterolemia awareness and treatment, 1980-1992
26. Variations in cholesterol management practices of U.S. physicians
27. Time trends in the use of cholesterol-lowering agents in older adults
28. Primary care practice adherence to national cholesterol education program guidelines for patients with coronary heart disease
29. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings?
30. Persistence of use of lipid-lowering medications
31. Inadequate treatment with HBG-Co A reductase inhibitors by health care providers
32. Use of cholesterol-lowering medications in the United States from 1991 to 1997
33. Relationship of dietary intake to hospital admission for coronary heart and vascular disease: The NHANES II national probability study
34. The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalizations and mortality: The prospective NHANES I follow-up study
35. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
36. Blood pressure as a cardiovascular risk factor
37. Prevalence of hypertension in the U.S. adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991
38. Use of antihypertensive drugs and trends in blood pressure in the elderly
39. Trends in pharmacologic management of hypertension in the United States
40. Temporal patterns of antihypertensive medication use among adults, 1989 through 1992
41. Trends in antihypertensive drug use in the United States: Do the JNC V recommendations affect prescribing?
42. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)
43. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
44. Pharmacologic treatment of hypertension in the department of Veterans Affairs during 1995 and 1996
45. A randomized trial of propanolol in patients with acute myocardial infarction. I. Mortality results
46. Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine
47. The risk of myocardial infarction associated with antihypertensive drug therapies
48. Calcium channel blockers and myocardial infarction: A hypothesis formulated but not yet tested
49. Is the calcium antagonist debate having an effect on clinical practice?
50. Factors influencing prescribing
51. Improving drug prescribing in primary care: A critical analysis of the experimental literature
52. Pharmaceutical advertisements in leading medical journals: Experts' assessments
53. The accuracy of drug information from pharmaceutical sales representatives
54. JNC guidelines: Is the message getting through?
55. Changing physician performance: A systematic review of the effect of continuing medical education strategies
56. Academic detailing to influence prescribing
57. Academic detailing to promote hypertension clinical practice guidelines
58. Organization of preventive cardiology service